

Kaiser Permanente Research Brief

Vaccines

This brief summarizes the contributions of Kaiser Permanente Research since 2007 on the topic of vaccines. This includes vaccinations delivered in early childhood as well as those delivered to adolescents and adults.

Although the development of vaccinations against communicable diseases dates back to the 18th century, the creation of modern vaccines and their widespread use in the United States began in the 20th century.¹ Today, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention provides national recommendations for 15 vaccines, including pertussis (whooping cough) shots for pregnant women and numerous vaccinations delivered to children, adolescents, and adults (see figure below).² Although vaccination has largely eliminated diseases such as measles and rubella in the United States,¹ these and others are still found frequently in countries with lower rates of vaccine coverage,³ and the ease of global travel has led to cases in which unvaccinated persons from well-vaccinated nations have contracted these infections.⁴ Moreover, diseases such as pertussis,¹ varicella (chicken pox)⁵ and human papillomavirus (HPV)⁶ still occur frequently in the United States.

In addition to the direct effect of immunizing patients against dangerous diseases, vaccination also benefits society more broadly through so-called “herd immunity” effects. Through herd immunity, higher rates of effective vaccination for a given illness at a population level confer protection to unvaccinated individuals by making encounters with infected individuals increasingly rare. For example, increased uptake of the pediatric pneumococcal vaccine has been associated with decreased rates of the disease among adults, many of whom have not, until recently, received this vaccine.^{7,8} The level of vaccination coverage required to create herd immunity for a given disease depends on both the

Kaiser Permanente Publications Related to Vaccines since 2007



Source: Kaiser Permanente Publications Library and PLUM metrics, as of October 19, 2020.

a Number of citing journal articles, according to Scopus.

b Number of references in PubMed guidelines.

c Citations in DynaMed Plus, a point-of-care clinical reference tool.

This brief summarizes a selection of the publications contained within the Kaiser Permanente Publications Library, which indexes journal articles and other publications authored by individuals affiliated with Kaiser Permanente. The work described in this brief originated from across Kaiser Permanente's 8 regions and was supported by a wide range of funding sources including internal research support as well as both governmental and nongovernmental extramural funding.

vaccine's effectiveness and how easily the disease is transmitted between unvaccinated persons.

Vaccination is an active area of study for Kaiser Permanente Research. Scientists across the organization have used our rich, comprehensive, longitudinal data to advance knowledge in the areas of understanding risk, improving patient outcomes, and translating research findings into policy and practice. We have published nearly 600 articles related to vaccines since 2007. Together, these articles have been cited approximately 14,000 times.

These articles are the product of observational studies, randomized controlled trials, meta-analyses, and other studies led by Kaiser Permanente scientists. Our unique environment, which includes our fully integrated care and coverage model, lets our research scientists, clinicians, medical groups, and health plan leaders collaborate to contribute generalizable knowledge on vaccines, and many other topics of research.

Understanding Risk

Kaiser Permanente researchers have contributed to understanding vaccine safety and the risks of acquiring vaccine-preventable diseases.

Who is at risk of acquiring vaccine-preventable communicable diseases?

Any person who has not been vaccinated against a particular disease and encounters a person infected with that disease is at risk of infection themselves. Additionally, no vaccine is 100% effective in preventing disease transmission, so vaccinated persons may continue to be at risk.^{9,10} In children, undervaccination (either delaying or not receiving vaccines) appears to be increasingly common.¹¹ Parental refusal of vaccines has been associated with outbreaks of measles, pertussis, varicella, Haemophilus influenzae type b (Hib), and pneumococcal disease,¹² and our recent studies have linked parental hesitancy with significantly higher rates of pertussis,¹³ varicella,¹⁴ and pneumococcal disease.¹⁵ Another study conducted by our scientists found lower rates of vaccination in children diagnosed with autism spectrum disorder, as well as their younger siblings.¹⁶ Our researchers also have found

higher rates of infection in children who failed to complete all courses of multicourse vaccines.¹⁷ In some instances, delaying vaccinations can increase the risk of side effects. For example, delayed receipt of measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccine has been associated with a higher risk of febrile seizures.¹⁸ Infants too young to be vaccinated against particular diseases are also at risk of acquiring those diseases; research has found that preterm infants may have lower immune

The CDC's Advisory Committee on Immunization Practices sets national guidelines for recommended vaccines.²

Childhood

(BIRTH TO 10 YEARS)

- Pertussis (during pregnancy)
- Diphtheria, Tetanus and Pertussis
- Hepatitis A, Hepatitis B
- Polio
- Pneumococcal
- Haemophilus Influenza Type B (Hib)
- Measles, Mumps, Rubella and Varicella
- Rotavirus
- Annual Flu (beginning at 6 months)



Adolescence

(11 TO 18 YEARS)

- Human Papillomavirus (HPV)
- Meningococcal Conjugate
- Tetanus, Diphtheria and Pertussis
- Annual Flu



Adulthood

(19+ YEARS)

- Annual Flu
- Tetanus and Diphtheria (with/without Pertussis)
- Herpes Zoster (at Age 50)



Kaiser Permanente scientists have developed and tested programs that address parental concerns about vaccinating their young children.



Beginning during pregnancy and continuing through infancy, physicians should provide information about vaccines, and work actively to build trust with hesitant parents¹⁰¹⁻¹⁰³

A website featuring vaccine information and social capabilities that allows parents to communicate and share information is associated with improved vaccination rates¹⁰⁶⁻¹⁰⁸



responses to vaccines,¹⁹ while neonatal intensive care unit-treated infants may not receive all appropriate vaccines.²⁰

In adults, our research has found higher risks of herpes zoster²¹ and influenza²² among the unvaccinated, and cervical cancer may be more common among women who do not receive HPV vaccination during adolescence.²³ Individuals with weakened immune systems also are at higher risk of acquiring vaccine-preventable diseases. For example, reactivation of latent herpes zoster infection is more likely to occur in patients using immunosuppressive drugs.²⁴

How safe are vaccines?

Because vaccines are, by definition, delivered to large numbers of healthy individuals, they are judged by very strict standards of safety, and regulatory approval is only granted to vaccines with extremely low observed risks. Kaiser Permanente researchers have been involved in studying the safety of meningococcal,²⁵⁻³⁵ pneumococcal,^{36,37} HPV,³⁸⁻⁴² MMR,⁴³ MMRV,⁴⁴⁻⁴⁶ tetanus-diphtheria-pertussis (Tdap),⁴⁷⁻⁵⁰ diphtheria-tetanus-pertussis (DTaP)-polio,⁵¹⁻⁵³ flu,⁵⁴⁻⁶⁸ shingles,⁶⁹ pertussis,⁷⁰

hepatitis A^{71,72} and hepatitis B⁷³ vaccines, among others.⁷⁴⁻⁷⁹ Nevertheless, the rarity of problems with vaccine safety makes the prediction of these risks challenging, and requires considerable research expertise^{80,81} and ongoing surveillance.⁸²⁻⁸⁴

Allergic reactions such as swelling or soreness at the vaccination site,⁸⁵⁻⁸⁸ and complications such as febrile seizures^{89,90} or fevers,^{91,92} are known side effects of vaccines, though these are rarely associated with long-term health problems.⁹³ Our scientists have led studies linking febrile seizure risks to specific vaccines, including the MMRV⁹⁴⁻⁹⁷ and influenza⁹⁸ vaccines. Elderly patients have also experienced higher rates of adverse effects from the shingles⁸⁶ and tetanus-diphtheria-pertussis (Tdap)⁹⁹ vaccines, although these risks are arguably outweighed by the benefits of these vaccines, such as prevention of neuralgic pain and tetanus or diphtheria infection.

Improving Patient Outcomes

What strategies are effective in increasing vaccination rates?

Our researchers have explored a variety of approaches for increasing vaccination rates. In general, the approaches used for early-childhood vaccination are very different from those used for other types of vaccines. Successful interventions for increasing vaccine uptake in young children include physician-oriented approaches to address parental hesitancy,¹⁰⁰⁻¹⁰⁵ tailored messages delivered via social media,¹⁰⁶⁻¹⁰⁹ school-based vaccination,¹¹⁰⁻¹¹³ and community-based education (for example, public-service announcements).^{114,115} In contrast, outreach approaches that have been shown to increase adolescent and adult uptake of vaccines include workplace vaccination programs^{116,117} and reminders placed in the electronic health records of patients or parents.^{110,118,119}

How effective is vaccination in preventing the transmission of communicable diseases?

Kaiser Permanente researchers have been actively involved in research on vaccine effectiveness, including herd immunity effects^{13,120-122} and pro-

tection of vulnerable populations, including the elderly,¹²³⁻¹²⁶ infants,¹²⁷⁻¹³³ those with suppressed immune systems,^{24,134} and people with certain chronic diseases.^{135,136} Other Kaiser Permanente research has identified shortcomings in vaccine effectiveness. Numerous studies of annual flu vaccinations have identified waning effects over time,¹³⁷⁻¹³⁹ differences in effectiveness between vaccine types,^{140,141} and variable effectiveness from year to year.^{22,142,143} More recently, we have repeatedly found evidence of the waning effectiveness of the pertussis¹⁴⁴⁻¹⁴⁹ and herpes zoster^{150,151} vaccines. This work contributed directly to changes in the ACIP's recommendations regarding immunization for these conditions. Finally, our scientists are actively involved in randomized trials evaluating the effectiveness of co-administering multiple vaccines to adolescents⁷⁷ and adults.⁷⁹

How does vaccination affect a person's health?

Vaccine-preventable diseases carry serious and well-known health risks, including cervical cancer from HPV, liver failure from hepatitis, meningitis from Hib, and death from illnesses such as influenza, pertussis, or hepatitis. Vaccination affects health in numerous ways beyond the transmission of communicable diseases. For example, vaccination in pregnant women has been shown to transmit immunity to their children,¹⁵²⁻¹⁵⁴ and annual flu vaccinations appear to have small but statistically significant effects on mortality and hospitalization rates,^{123,155-158} and on numbers of outpatient visits.¹⁵⁹

Translating Research Findings Into Policy and Practice


How has Kaiser Permanente research on vaccines contributed to changes in policy and practice?

As part of a learning health care organization that uses research to inform and improve practice, our research, clinical, and operational partners have tested a range of interventions to increase uptake of recommended vaccines. Pediatricians in Kaiser Permanente have worked to address

parental vaccine hesitancy,^{101,160,161} leading to the development and evaluation of messaging interventions.^{102,107} This work was subsequently expanded to flu and HPV vaccination. Reminders placed in Kaiser Permanente's electronic health record system have been used to inform changes in vaccination policies,^{84,162-165} including a change in herpes zoster vaccines. Our scientists have also explored multicomponent programs for increasing rates of HPV vaccination.¹⁶⁶

Collectively, research from Kaiser Permanente authors has been cited more than 200 times in recent consensus statements, and in the vaccination guidelines for influenza,¹⁶⁷ HPV,¹⁶⁸ herpes zoster,¹⁶⁹ Tdap¹⁷⁰ and MMRV¹⁷¹ published by the CDC's Morbidity and Mortality Weekly Report. Our research has also directly influenced national vaccines policies. One study of febrile seizure risks associated with the first injection of MMRV versus MMR separately from varicella found that

The Vaccine Safety Data link demonstrated increased seizure risk with MMRV versus delivering MMR and varicella in separate injections.⁹⁴



those receiving MMRV were twice as likely to experience seizures 7 to 10 days after vaccination.⁹⁴ This led the CDC to recommend that the first MMR and varicella shots be given separately (unless the parent wishes their child to receive MMRV).^{18,171} Work questioning the durability of the pertussis vaccine delivered to children^{145,149} led to increased emphasis on prenatal vaccination,¹⁵² and other work¹⁵⁰ prompted uptake of a newer zoster vaccine.¹⁵¹

Kaiser Permanente has also shown considerable leadership in the field of vaccine research. Our researchers are leaders in the CDC's Vaccine Safety Datalink, or VSD, an ongoing effort to use data from large health care organizations to evaluate vaccine safety.^{172,173} In the VSD, which began in 1990, 5 of our regions contribute electronic patient data that are used to study rare but serious adverse reactions, and monitor the safety of new vaccines or changes in vaccine recommendations. Vaccine safety in pregnancy is an emphasis of VSD research, along with the development of new research methods and rapid cycle analysis techniques for promptly notifying the public of possible risks.¹⁷⁴⁻¹⁷⁷ We are also involved in the U.S. Flu Vaccine Effectiveness Network, which provides interim and annual estimates of the effectiveness of each year's flu vaccine by studying individuals entering health care facilities during flu season.¹⁷⁸⁻¹⁸⁴ Our researchers continue to be involved in early-stage vaccine development through the large, long-standing vaccine clinical trials program in the Northern California Vaccine Study Center, and through the National Institutes of Health's Vaccine and Treatment Evaluation Network.¹⁸⁵ The VTEU, based in Kaiser Permanente's Washington Region, is the only such unit in the country housed in an integrated health system. Finally, our scientists are part of numerous vaccine clinical trials in response to the COVID-19 pandemic. The VTEU was the lead site for the first-ever trial of a COVID-19 vaccine, evaluating the vaccine developed by Moderna Therapeutics and the National Institute of Allergy and Infectious Diseases.^{186,187} Our researchers were involved in several late-phase efficacy trials, including trials of the vaccines developed by Pfizer, Inc. and BioNTech, Moderna/NIAID, and Johnson & Johnson.¹⁸⁸

Kaiser Permanente's nearly 170 research scientists and more than 1,600 support staff are based at 8 regional research centers and 1 national center. There are currently more than 2,400 studies underway, including clinical trials. Since 2007 our research scientists have published more than 12,000 articles in peer-reviewed journals. Kaiser Permanente currently serves more than 12.4 million members in 8 states and the District of Columbia.

This brief was written by Nicholas P. Emptage, Anna C. Davis, and Elizabeth A. McGlynn. It is available online at about.kaiserpermanente.org/our-story/health-research/research-briefs. The authors wish to thank the following researchers for their contributions to the development of this brief: Nicola P. Klein, Jason M. Glanz, and Lisa A. Jackson.

References

1. Ventola CL. Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations. *P t*. 2016;41(7):426-436.
2. Centers for Disease Control and Prevention. ACIP Vaccine Recommendations. 2018; <https://www.cdc.gov/vaccines/hcp/acip-recs/index.html>. Accessed July 6, 2018.
3. World Health Organization. Global Alliance for Vaccines and Immunization (GAVI). 2018; <http://www.who.int/mediacentre/factsheets/fs169/en/>. Accessed July 6, 2018.
4. Gautret P, Botelho-Nevers E, Brouqui P, Parola P. The spread of vaccine-preventable diseases by international travellers: a public-health concern. *Clin Microbiol Infect*. 2012;18 Suppl 5:77-84.
5. Centers for Disease Control and Prevention. Monitoring the Impact of Varicella Vaccination. 2016; <https://www.cdc.gov/chickenpox/surveillance/monitoring-varicella.html>. Accessed July 6, 2018.
6. Centers for Disease Control and Prevention. Human Papillomavirus (HPV) Statistics. 2017; <https://www.cdc.gov/std/hpv/stats.htm>. Accessed July 6, 2018.
7. Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in *Streptococcus pneumoniae* after introduction of the pneumococcal conjugate vaccine: population-based assessment. *Lancet*. 2005;365(9462):855-863.
8. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med*. 2003;348(18):1737-1746.
9. Chu L, Daganzo S, Aronowitz P. Chickenpox in a Vaccinated Adult. *J Gen Intern Med*. 2019;34(3):479-480.
10. Zerbo O, Bartlett J, Goddard K, et al. Acellular Pertussis Vaccine Effectiveness Over Time. *Pediatrics*. 2019.
11. Glanz JM, Newcomer SR, Narwaney KJ, et al. A Population-Based Cohort Study of Undervaccination in 8 Managed Care Organizations Across the United States. *JAMA Pediatr*. 2013;167(3):274-281.
12. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine Hesitancy: Causes, Consequences, and a Call to Action. *Am J Prev Med*. 2015;49(6 Suppl 4):S391-398.
13. Glanz JM, McClure DL, Magid DJ, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. *Pediatrics*. 2009;123(6):1446-1451.
14. Glanz JM, McClure DL, Magid DJ, et al. Parental refusal of varicella vaccination and the associated risk of varicella infection in children. *Arch Pediatr Adolesc Med*. 2010;164(1):66-70.
15. Glanz JM, McClure DL, O'Leary ST, et al. Parental decline of pneumococcal vaccination and risk of pneumococcal related disease in children. *Vaccine*. 2011;29(5):994-999.
16. Zerbo O, Modaresi S, Goddard K, et al. Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings. *JAMA Pediatr*. 2018.
17. Glanz JM, Narwaney KJ, Newcomer SR, et al. Association Between Undervaccination With Diphtheria, Tetanus Toxoids, and Acellular Pertussis (DTaP) Vaccine and Risk of Pertussis Infection in Children 3 to 36 Months of Age. *JAMA Pediatr*. 2013;167(11):1060-1064.
18. Hambidge SJ, Newcomer SR, Narwaney KJ, et al. Timely Versus Delayed Early Childhood Vaccination and Seizures. *Pediatrics*. 2014;133(6):e1492-1499.
19. Klein NP, Gans HA, Sung P, et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. *J Infect Dis*. 2010;201(2):214-222.
20. Navar-Boggan AM, Halsey NA, Escobar GJ, et al. Underimmunization at discharge from the neonatal intensive care unit. *J Perinatol*. 2012;32(5):363-367.
21. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. *JAMA*. 2011;305(2):160-166.
22. Jackson ML, Chung JR, Jackson LA, et al. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. *N Engl J Med*. 2017;377(6):534-543.
23. Silverberg MJ, Leyden WA, Lam JO, et al. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. *Lancet Child Adolesc Health*. 2018;2(10):707-714.
24. Cheetham TC, Marcy SM, Tseng HF, et al. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. *Mayo Clin Proc*. 2015;90(7):865-873.
25. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. *Clin Infect Dis*. 2009;49(1):e1-10.
26. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. *Clin Vaccine Immunol*. 2009;16(12):1810-1815.

27. Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. *Vaccine*. 2010;28(50):7865-7872.
28. Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. *Pediatr Infect Dis J*. 2011;30(3):e41-48.
29. Baxter R, Baine Y, Kolhe D, et al. Five-Year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W, and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial. *Pediatr Infect Dis J*. 2015;34(11):1236-1243.
30. Klein NP, Reisinger KS, Johnston W, et al. Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-Conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants. *Pediatr Infect Dis J*. 2012;31(1):64-71.
31. Klein NP, Baine Y, Bianco V, et al. One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine is Immunogenic in 9-12 Month Old Children. *Pediatr Infect Dis J*. 2013;32(7):760-767.
32. Klein NP, Baine Y, Kolhe D, et al. Five-Year Antibody Persistence and Booster Response Following One or Two Doses of Meningococcal A, C, W, and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. *Pediatr Infect Dis J*. 2016;35(6):662-672.
33. Klein NP, Habanec T, Kosina P, et al. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. *Vaccine*. 2018;36(17):2356-2363.
34. Tseng HF, Sy LS, Ackerson BK, et al. Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. *Pediatrics*. 2017;139(1).
35. Tartof SY, Sy LS, Ackerson BK, et al. Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2-10 Years. *Pediatr Infect Dis J*. 2017;36(11):1087-1092.
36. Greenhow TL, Hung YY, Herz A. Bacteremia in Children 3 to 36 Months Old After Introduction of Conjugated Pneumococcal Vaccines. *Pediatrics*. 2017;139(4).
37. Tseng HF, Sy LS, Qian L, et al. Pneumococcal Conjugate Vaccine Safety in Elderly Adults. *Open Forum Infect Dis*. 2018;5(6):ofy100.
38. Vichnin M, Bonanni P, Klein NP, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety - 2006 to 2015. *Pediatr Infect Dis J*. 2015;34(9):983-991.
39. Sy LS, Meyer KI, Klein NP, et al. Postlicensure Safety Surveillance of Congenital Anomaly and Miscarriage Among Pregnancies Exposed to Quadrivalent Human Papillomavirus Vaccine. *Hum Vaccin Immunother*. 2018;14(2):412-419.
40. Naleway AL, Mittendorf KF, Irving SA, et al. Primary Ovarian Insufficiency and Adolescent Vaccination. *Pediatrics*. 2018;142(3).
41. Lipkind HS, Vazquez-Benitez G, Nordin JD, et al. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. *Obstet Gynecol*. 2017;130(3):599-608.
42. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. *Obstet Gynecol*. 2018;132(1):35-44.
43. Klein NP, Abu-Elyazeed R, Povey M, et al. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. *J Pediatric Infect Dis Soc*. 2019.
44. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Co-Administered with Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age. *Pediatr Infect Dis J*. 2012;31(8):e133-140.
45. Leonardi M, Bromberg K, Baxter R, et al. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. *Pediatrics*. 2011;128(6):e1387-1394.
46. Klein NP, Weston WM, Kuriyakose S, et al. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. *Vaccine*. 2012;30(3):668-674.
47. DeSilva M, Vazquez-Benitez G, Nordin JD, et al. Maternal Tdap vaccination and risk of infant morbidity. *Vaccine*. 2017;35(29):3655-3660.
48. Jackson ML, Yu O, Nelson JC, et al. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. *Pharmacoepidemiol Drug Saf*. 2018;27(8):921-925.
49. Becerra-Culqui TA, Getahun D, Chiu V, et al. Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. *Pediatrics*. 2018.
50. Becerra-Culqui TA, Getahun D, Chiu V, et al. Prenatal tetanus, diphtheria, acellular pertussis vaccination and attention deficit hyperactivity disorder. *Am J Epidemiol*. 2020.

51. Weston WM, Klein NP. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. *Expert Rev Vaccines*. 2008;7(9):1309-1320.
52. Black S, Friedland LR, Ensor K, et al. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. *Pediatr Infect Dis J*. 2008;27(4):341-346.
53. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Infant Hospitalizations and Mortality After Maternal Vaccination. *Pediatrics*. 2018;141(3).
54. Jain VK, Domachowske JB, Wang L, et al. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. *J Pediatric Infect Dis Soc*. 2017;6(1):9-19.
55. Baxter R, Jeanfreau R, Block SL, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. *Pediatr Infect Dis J*. 2010;29(10):924-930.
56. Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. *Am J Prev Med*. 2011;41(2):121-128.
57. Kawai AT, Li L, Kulldorff M, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barre syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. *Pharmacoepidemiol Drug Saf*. 2014;23(5):548-553.
58. Li R, Stewart B, McNeil MM, et al. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. *Pharmacoepidemiol Drug Saf*. 2016;25(8):928-934.
59. Baxter RP, Lewis N, Fireman B, et al. Live Attenuated Influenza Vaccination Prior To Age 3 Years and Subsequent Development of Asthma: A 14-Year Follow-Up Study. *Pediatr Infect Dis J*. 2018;37(5):383-386.
60. Kharbanda EO, Vazquez-Benitez G, Romitti PA, et al. First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. *J Pediatr*. 2017;187:234-239.
61. Baxter R, Eaton A, Hansen J, et al. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years. *Vaccine*. 2017;35(9):1254-1258.
62. Zerbo O, Modaresi S, Chan B, et al. No association between influenza vaccination during pregnancy and adverse birth outcomes. *Vaccine*. 2017;35(24):3186-3190.
63. Ray GT, Lewis N, Goddard K, et al. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. *Vaccine*. 2017;35(20):2668-2675.
64. Vickers ER, McClure DL, Naleway AL, et al. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. *Vaccine*. 2017;35(43):5872-5877.
65. Daley MF, Clarke CL, Glanz JM, et al. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. *Pharmacoepidemiol Drug Saf*. 2017;27(1):59-68.
66. Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. *Vaccine*. 2019.
67. Getahun D, Fassett MJ, Peltier MR, et al. Association between seasonal influenza vaccination with pre- and postnatal outcomes. *Vaccine*. 2019.
68. Munoz FM, Jackson LA, Swamy GK, et al. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. *Vaccine*. 2018.
69. Gruppung K, Campora L, Douha M, et al. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine. *J Infect Dis*. 2017;216(11):1343-1351.
70. Chatterjee A, O'Keefe C, Varman M, et al. Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study. *Vaccine*. 2012;30(23):3360-3368.
71. Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine When Coadministered With Diphtheria-tetanus-acellular Pertussis and Haemophilus influenzae Type B Vaccines in Children 15 Months of Age. *Pediatr Infect Dis J*. 2011;30(9):e164-169.
72. Groom HC, Smith N, Irving SA, et al. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. *Vaccine*. 2019.
73. Groom HC, Irving SA, Koppolu P, et al. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. *Vaccine*. 2018;36(41):6111-6116.
74. Glanz JM, Newcomer SR, Daley MF, et al. Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age. *JAMA*. 2018;319(9):906-913.
75. Hansen J, Zhang L, Klein NP, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. *Vaccine*. 2017;35(49 Pt B):6879-6884.
76. Wang SV, Abdurrob A, Spoendlin J, et al. Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines. *Pharmacoepidemiol Drug Saf*. 2018;27(4):405-412.

77. Klein NP, Abu-Elyazeed R, Cheuvart B, et al. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. *Hum Vaccin Immunother.* 2019;15(4):809-821.
78. Klein NP, Abu-Elyazeed R, Baine Y, et al. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants. *Hum Vaccin Immunother.* 2019;15(2):327-338.
79. Thompson AR, Klein NP, Downey HJ, et al. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. *Hum Vaccin Immunother.* 2019;15(2):444-451.
80. Williams SE, Pahud BA, Vellozzi C, et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. *Vaccine.* 2011;29(46):8302-8308.
81. Rowhani-Rahbar A, Klein NP, Dekker CL, et al. Biologically plausible and evidence-based risk intervals in immunization safety research. *Vaccine.* 2012;31(1):271-277.
82. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. *Pediatrics.* 2011;127(Suppl 1):S45-53.
83. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. *Med Care.* 2007;45(10 Suppl 2):S89-95.
84. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. *Pediatrics.* 2011;127(Suppl 1):S54-64.
85. Glanz JM, Newcomer SR, Hambidge SJ, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. *Arch Pediatr Adolesc Med.* 2011;165(8):749-755.
86. Tseng HF, Liu A, Sy L, et al. Safety of Zoster Vaccine in Adults from a Large Managed Care Cohort: A Vaccine Safety Datalink Study. *J Intern Med.* 2012;271(5):510-520.
87. Loughlin AM, Marchant CD, Adams W, et al. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). *Vaccine.* 2012;30(50):7253-7259.
88. Jackson LA, Yu O, Nelson JC, et al. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. *Pediatrics.* 2011;127(3):e581-587.
89. Duffy J, Weintraub E, Hambidge SJ, et al. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. *Pediatrics.* 2016;138(1).
90. Duffy J, Hambidge SJ, Jackson LA, et al. Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. *Pediatr Neurol.* 2017;76:72-78.
91. Klein NP, Lewis E, McDonald J, et al. Risk factors and familial clustering for fever 7-10days after the first dose of measles vaccines. *Vaccine.* 2017;35(12):1615-1621.
92. Walter EB, Klein NP, Wodi AP, et al. Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. *Pediatrics.* 2020.
93. Tartof SY, Tseng HF, Liu IL, et al. Inpatient admission for febrile seizure and subsequent outcomes do not differ in children with vaccine-associated versus non-vaccine associated febrile seizures. *Vaccine.* 2014;32(48):6408-6414.
94. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. *Pediatrics.* 2010;126(1):e1-8.
95. Klein NP, Lewis E, Fireman B, et al. Safety of Measles-Containing Vaccines in 1-Year-Old Children. *Pediatrics.* 2015;135(2):e321-329.
96. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. *Vaccine.* 2009;27(34):4656-4661.
97. Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in Children. *JAMA Pediatr.* 2013;167(12):1111-1117.
98. Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. *Vaccine.* 2012;30(11):2024-2031.
99. Tseng HF, Sy LS, Qian L, et al. Safety of a Tetanus-Diphtheria-Acellular Pertussis Vaccine When Used Off-Label in an Elderly Population. *Clin Infect Dis.* 2013;56(3):315-321.
100. Sadaf A, Richards JL, Glanz J, et al. A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy. *Vaccine.* 2013;31(40):4293-4304.
101. Glanz JM, Wagner NM, Narwaney KJ, et al. A mixed methods study of parental vaccine decision making and parent-provider trust. *Acad Pediatr.* 2013;13(5):481-488.
102. Glanz JM, Kraus CR, Daley MF. Addressing Parental Vaccine Concerns: Engagement, Balance, and Timing. *PLoS Biol.* 2015;13(8):e1002227.

103. Opel DJ, Zhou C, Robinson JD, et al. Impact of the Childhood Vaccine Discussion Format Over Time on Immunization Status. *Acad Pediatr*. 2018;18(4):430-436.
104. Lieu TA, Zikmund-Fisher BJ, Chou C, et al. Parents' Perspectives on How to Improve the Childhood Vaccination Process. *Clin Pediatr (Phila)*. 2017;56(3):238-246.
105. Eller NM, Henrikson NB, Opel DJ. Vaccine Information Sources and Parental Trust in Their Child's Health Care Provider. *Health Educ Behav*. 2019.
106. Glanz JM, Wagner NM, Narwaney KJ, et al. Web-based Social Media Intervention to Increase Vaccine Acceptance: A Randomized Controlled Trial. *Pediatrics*. 2017;140(6):e20171117.
107. Shoup JA, Wagner NM, Kraus CR, et al. Development of an Interactive Social Media Tool for Parents With Concerns About Vaccines. *Health Educ Behav*. 2015;42(3):302-312.
108. Daley MF, Narwaney KJ, Shoup JA, et al. Addressing Parents' Vaccine Concerns: A Randomized Trial of a Social Media Intervention. *Am J Prev Med*. 2018;55(1):44-54.
109. Shoup JA, Narwaney KJ, Wagner NM, et al. Social Media Vaccine Websites: A Comparative Analysis of Public and Moderated Websites. *Health Educ Behav*. 2019;46(3):454-462.
110. Daley MF, Curtis CR, Pyrzanowski J, et al. Adolescent immunization delivery in school-based health centers: a national survey. *J Adolesc Health*. 2009;45(5):445-452.
111. Gold R, Naleway AL, Jenkins LL, et al. Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. *Prev Med*. 2011;52(6):456-458.
112. Kjos SA, Irving SA, Meece JK, Belongia EA. Elementary school-based influenza vaccination: evaluating impact on respiratory illness absenteeism and laboratory-confirmed influenza. *PLoS ONE*. 2013;8(8):e72243.
113. Kempe A, Allison MA, Daley MF. Can School-Located Vaccination Have a Major Impact on Human Papillomavirus Vaccination Rates in the United States? *Acad Pediatr*. 2018;18(2S):S101-S105.
114. Kepka D, Coronado GD, Rodriguez HP, Thompson B. Evaluation of a Radionovela to Promote HPV Vaccine Awareness and Knowledge Among Hispanic Parents. *J Community Health*. 2011;36(6):957-965.
115. Schoeppe J, Cheadle A, Melton M, et al. The Immunity Community: A Community Engagement Strategy for Reducing Vaccine Hesitancy. *Health Promot Pract*. 2017;18(5):654-661.
116. Kuntz JL, Holley S, Helms CM, et al. Use of a pandemic preparedness drill to increase rates of influenza vaccination among healthcare workers. *Infect Control Hosp Epidemiol*. 2008;29(2):111-115.
117. Naleway AL, Henkle EM, Ball S, et al. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. *Am J Infect Control*. 2014;42(4):371-375.
118. Tom JO, Chen C, Zhou YY. Personal Health Record Use and Association with Immunizations and Well-Child Care Visits Recommendations. *J Pediatr*. 2014;164(1):112-117.
119. Henrikson NB, Zhu W, Baba L, et al. Outreach and Reminders to Improve Human Papillomavirus Vaccination in an Integrated Primary Care System. *Clin Pediatr (Phila)*. 2018;57(13):1523-1531.
120. Baxter R, Tran TN, Ray P, et al. Impact of Vaccination on the Epidemiology of Varicella: 1995-2009. *Pediatrics*. 2014;134(1):24-30.
121. Markowitz LE, Naleway AL, Lewis RM, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. *Vaccine*. 2019;37(29):3918-3924.
122. Baxter R, Aukes L, Pelton SI, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. *J Pediatric Infect Dis Soc*. 2020.
123. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med*. 2007;357(14):1373-1381.
124. Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. *J Infect Dis*. 2012;206(2):190-196.
125. Russell K, Chung JR, Monto AS, et al. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. *Vaccine*. 2018;36(10):1272-1278.
126. Jackson LA, El Sahly HM, George S, et al. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine*. 2018;36(5):606-614.
127. Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. *JAMA*. 2012;307(6):598-604.
128. Yih WK, Lieu TA, Kulldorff M, et al. Intussusception Risk after Rotavirus Vaccination in U.S. Infants. *N Engl J Med*. 2014;370(6):503-512.
129. Eaton A, Lewis N, Fireman B, et al. Birth outcomes following immunization of pregnant women with pandemic H1N1 influenza vaccine 2009-2010. *Vaccine*. 2018;36(19):2733-2739.
130. Block SL, Klein NP, Sarpong K, et al. Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants. *Pediatr Infect Dis J*. 2017;36(2):202-208.

131. Klein NP, Abu-Elyazeed R, Cornish M, et al. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. *Vaccine*. 2017;35(28):3564-3574.
132. Avalos LA, Ferber J, Zerbo O, et al. Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development. *Vaccine*. 2020;38(10):2326-2332.
133. Platt HL, Greenberg D, Tapiero B, et al. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. *Pediatr Infect Dis J*. 2020;39(8):763-770.
134. Tseng HF, Tartof S, Harpaz R, et al. Vaccination Against Zoster Remains Effective in Older Adults Who Later Undergo Chemotherapy. *Clin Infect Dis*. 2014;59(7):913-919.
135. Henkle E, Lu M, Rupp LB, et al. Hepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C Patients in a Large United States Cohort. *Clin Infect Dis*. 2015;60(4):514-522.
136. Shang M, Chung JR, Jackson ML, et al. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. *Vaccine*. 2018.
137. Bateman AC, Kieke BA, Irving SA, et al. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. *J Infect Dis*. 2013;207(8):1262-1269.
138. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. *Clin Infect Dis*. 2017;64(5):544-550.
139. Ray GT, Lewis N, Klein NP, et al. Intra-season Waning of Influenza Vaccine Effectiveness. *Clin Infect Dis*. 2018.
140. Poehling KA, Caspard H, Peters TR, et al. 2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. *Clin Infect Dis*. 2018;66(5):665-672.
141. Klein NP, Fireman B, Goddard K, et al. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. *PLoS ONE*. 2020;15(2):e0229279. Epub 0222020-0229202.
142. Cochran LW, Black S, Klein NP, et al. Vaccine effectiveness against laboratory-confirmed influenza in infants: A matched case control study. *Hum Vaccin*. 2010;6(9):729-735.
143. Flannery B, Smith C, Garten RJ, et al. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. *J Infect Dis*. 2018;218(2):189-196.
144. Witt MA, Katz PH, Witt DJ. Unexpectedly Limited Durability of Immunity Following Acellular Pertussis Vaccination in Pre-Adolescents in a North American Outbreak. *Clin Infect Dis*. 2012;54(12):1730-1735.
145. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. *Pediatrics*. 2013;131(4):e1047-1052.
146. Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap Effectiveness in Adolescents. *Pediatrics*. 2016;137(3):e20153326.
147. Klein NP, Bartlett J, Fireman B, et al. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. *Vaccine*. 2017;35(26):3395-3400.
148. Briere EC, Pondo T, Schmidt M, et al. Assessment of Tdap Vaccination Effectiveness in Adolescents in Integrated Health-Care Systems. *J Adolesc Health*. 2018;62(6):661-666.
149. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. *N Engl J Med*. 2012;367(11):1012-1019.
150. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults 60 years and older. *J Infect Dis*. 2016;213(12):1872-1875.
151. Baxter R, Bartlett J, Fireman B, et al. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. *Am J Epidemiol*. 2018;187(1):161-169.
152. Baxter R, Bartlett J, Fireman B, et al. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. *Pediatrics*. 2017;139(5):e20164091.
153. Henkle E, Steinhoff MC, Omer SB, et al. The Effect of Exclusive Breastfeeding on Respiratory Illness in Young Infants in a Maternal Immunization Trial in Bangladesh. *Pediatr Infect Dis J*. 2013;32(5):431-435.
154. Coonrod DV, Jack BW, Boggess KA, et al. The clinical content of preconception care: immunizations as part of preconception care. *Am J Obstet Gynecol*. 2008;199(6 Suppl 2):S290-295.
155. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. *Vaccine*. 2010;28(45):7267-7272.
156. Fireman B, Lee J, Lewis N, et al. Influenza vaccination and mortality: differentiating vaccine effects from bias. *Am J Epidemiol*. 2009;170(5):650-656.
157. Nelson JC, Jackson ML, Jackson LA. Effectiveness of influenza vaccination. *N Engl J Med*. 2007;357(26):2728-2729.

158. Thompson MG, Kwong JC, Regan AK, et al. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016. *Clin Infect Dis*. 2018.
159. Jackson ML, Phillips CH, Benoit J, et al. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. *Vaccine*. 2018;36(4):467-472.
160. Henrikson NB, Anderson ML, Opel DJ, et al. Longitudinal Trends in Vaccine Hesitancy in a Cohort of Mothers Surveyed in Washington State, 2013-2015. *Public Health Rep*. 2017;132(4):451-454.
161. Widdice LE, Hoagland R, Callahan ST, et al. Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series. *Vaccine*. 2018;36(11):1491-1499.
162. McCarthy NL, Gee J, Weintraub E, et al. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. *Vaccine*. 2011;29(31):4891-4896.
163. Chao C, Silverberg MJ, Becerra TA, et al. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system. *Am J Obstet Gynecol*. 2017;216(2-151):e1-e9.
164. Hechter RC, Qian L, Luo Y, et al. Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus. *Vaccine*. 2019;37(1):195-201.
165. Bruxvoort K, Sy LS, Luo Y, Tseng HF. Real World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine. *Am J Epidemiol*. 2018.
166. Groom HC, Irving SA, Caldwell J, et al. Implementing a Multipartner HPV Vaccination Assessment and Feedback Intervention in an Integrated Health System. *J Public Health Manag Pract*. 2017;23(6):589-592.
167. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. *MMWR Recomm Rep*. 2017;66(2):1-20.
168. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2014;63(Rr-05):1-30.
169. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. *MMWR Morb Mortal Wkly Rep*. 2018;67(3):103-108.
170. Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2018;67(2):1-44.
171. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2010;59(Rr-3):1-12.
172. Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD). 2018; <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/>. Accessed July 6, 2018.
173. Hambidge SJ, Ross C, Shoup JA, et al. Integration of data from a safety net health care system into the Vaccine Safety Datalink. *Vaccine*. 2017;35(9):1329-1334.
174. McNeil MM, Gee J, Weintraub ES, et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. *Vaccine*. 2014;32(42):5390-5398.
175. Li R, Weintraub E, McNeil MM, et al. Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method. *Pharmacoepidemiol Drug Saf*. 2018;27(4):391-397.
176. Kharbanda EO, Vazquez-Benitez G, Romitti PA, et al. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. *Pharmacoepidemiol Drug Saf*. 2017;26(4):412-420.
177. Donahue JG, Kieke BA, Lewis EM, et al. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. *Pediatrics*. 2019.
178. Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2005-2018. 2018; <https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm>. Accessed July 6, 2018.
179. Doyle JD, Chung JR, Kim SS, et al. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019. *MMWR Morb Mortal Wkly Rep*. 2019;68(6):135-139.
180. Flannery B, Chung JR, Monto AS, et al. Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season. *Clin Infect Dis*. 2019;68(11):1798-1806.
181. Rolfes MA, Flannery B, Chung J, et al. Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season. *Clin Infect Dis*. 2019.
182. Dawood FS, Chung JR, Kim SS, et al. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(7):177-182.
183. Flannery B, Kondor RJG, Chung JR, et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season. *J Infect Dis*. 2019.
184. Chung JR, Flannery B, Gaglani M, et al. Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness. *JAMA Pediatr*. 2020.
185. National Institute of Allergy and Infectious Diseases. Vaccine and Treatment Evaluation Units (VTEUs). 2017; <https://www.niaid.nih.gov/research/vaccine-treatment-evaluation-units>. Accessed July 6, 2018.
186. Jackson LA, Anderson EJ, Roupheal NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*. 2020.

-
187. Anderson EJ, Roupael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med*. 2020.
 188. Kaiser Permanente joins late-stage COVID-19 vaccine study [press release]. August, 12, 2020 2020.